These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 7108936)

  • 1. Increased level of the complement C3 protein in endogenous hypertriglyceridemia.
    Uza G; Cristea A; Cucuianu MP
    J Clin Lab Immunol; 1982 Jun; 8(2):101-5. PubMed ID: 7108936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Behaviour of uricemia in hyperlipoproteinemic subjects.
    Zdrenghea D; Marta D; Constantinescu M; Cucuianu M
    Med Interne; 1980; 18(4):385-90. PubMed ID: 7455583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased plasma level of clotting factors VII and X in hyperlipoproteinemia.
    Cucuianu M; Popescu TA; Roman S; Bedeleanu D; Păiş R
    Med Interne; 1985; 23(1):37-43. PubMed ID: 3992146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased values of antipyrine clearance in type IV hyperlipoproteinemia.
    Bedeleanu D; Trif I; Lötsch JC; Cucuianu MP
    Med Interne; 1986; 24(3):183-90. PubMed ID: 3775212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased plasma antithrombin III level in hyperlipidemic subjects.
    Cucuianu MP; Cristea A; Roman S; Missits I
    Clin Chim Acta; 1981 Mar; 110(2-3):147-55. PubMed ID: 7226527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of complement factor C3, but not factor B, increases hyperlipidemia and atherosclerosis in apolipoprotein E-/- low-density lipoprotein receptor-/- mice.
    Persson L; Borén J; Robertson AK; Wallenius V; Hansson GK; Pekna M
    Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1062-7. PubMed ID: 15059809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypercatabolism of the third component of complement in patients with primary biliary cirrhosis.
    Potter BJ; Elias E; Jones EA
    J Lab Clin Med; 1976 Sep; 88(3):427-39. PubMed ID: 956695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of aging on complement activity (CH50) and complement protein levels.
    Nagaki K; Hiramatsu S; Inai S; Sasaki A
    J Clin Lab Immunol; 1980 Jan; 3(1):45-50. PubMed ID: 7381926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
    Noseda G; Fragiacomo C; Weidmann P; Bachmann C
    Schweiz Med Wochenschr; 1980 Dec; 110(49):1875-7. PubMed ID: 7455660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pirifibrate in the treatment of hyperlipoproteinemia: types IIa, IIb, and IV.
    Lopez Rodriguez J; Martorell J
    Clin Ther; 1980; 3(4):234-41. PubMed ID: 7273061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical studies on plasma protein C. Correlation with serum cholinesterase.
    Cucuianu M; Brudasca I; Trif I; Stancu A
    Nouv Rev Fr Hematol (1978); 1993; 35(5):481-6. PubMed ID: 8295822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Alcohol-induced hyperlipoproteinemia].
    Baumgartner HP; Filippini L
    Schweiz Med Wochenschr; 1977 Oct; 107(40):1406-11. PubMed ID: 918592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variable effects of soy protein on plasma lipids in hyperlipidemic and normolipidemic hemodialysis patients.
    Chen ST; Ferng SH; Yang CS; Peng SJ; Lee HR; Chen JR
    Am J Kidney Dis; 2005 Dec; 46(6):1099-106. PubMed ID: 16310576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Apolipoprotein E and activity of cholesterol esters transport in type IIA and IIB hyperlipoproteinemia].
    Tvorogova MG; Rozhkova TA; Semenova OA; Lupanov VP; Nuraliev EIu ; Kukharchuk VV; Titov VN
    Ter Arkh; 1997; 69(12):30-3. PubMed ID: 9503530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical experience with bezafibrate.
    Schubotz R; Schneider J; Hausmann L; Mühlfellner G; Mühlfellner O; Kaffarnik H
    Artery; 1980; 8(6):553-9. PubMed ID: 7259534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pirifibrate in the treatment of hyperlipoproteinemias: a multicenter study.
    Domingo AJ; Gutiérrez JA; Menéndez JA; Micó L; Muñoz M; de Oya M
    Clin Ther; 1980; 3(3):219-26. PubMed ID: 7459931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemorrheologic abnormalities in defined primary dyslipoproteinemias with both high and low atherosclerotic risks.
    Otto C; Ritter MM; Richter WO; Minkenberg R; Schwandt P
    Metabolism; 2001 Feb; 50(2):166-70. PubMed ID: 11229424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The effects of a short-lasting hyperthermia on the levels of complement and lysosomal enzymes in the serum of healthy and IHD-sick subjects].
    Ferenciková J; Kolesár J
    Allerg Immunol (Leipz); 1982; 28(2):122-8. PubMed ID: 6215845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Components of complement in patients with immediate hypersensitivity].
    Anania A; Massobrio AM; Cascio B; Bosso E; Cascio G
    Minerva Med; 1998 Mar; 89(3):77-81. PubMed ID: 9575333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical study on the effect of simvastatin on butyrylcholinesterase activity.
    Muacević-Kataneca D; Bradamante V; Reinec Z; Sucić M; Poljicanin T; Busljeta I; Metelko Z
    Arzneimittelforschung; 2005; 55(5):271-5. PubMed ID: 15960426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.